LifeStance Health Group filings document the company's outpatient mental healthcare business, Nasdaq-listed common stock and public-company governance. Its 8-K reports furnish quarterly and annual results, Regulation FD presentations, operating metrics, cash flow commentary and capital allocation disclosures.
The filing record also covers proxy matters, director elections, executive compensation, officer and board changes, equity incentive awards, share repurchase authorization, and common stock offering documents under shelf registration statements. These disclosures describe governance structure, securities registration, material agreements, stockholder selling activity, repurchases, and the risks and reporting obligations associated with LifeStance's virtual and in-person outpatient care model.
LifeStance Health Group, Inc. (LFST) said Teresa DeLuca, M.D. notified its board on October 14, 2026, that she will resign from the board and all of its committees effective December 31, 2026. The company stated that her resignation is not the result of a disagreement with the company.
LifeStance Health Group, Inc. (LFST) is the subject of an amended beneficial-ownership report by BlackRock, Inc., which reported 38,673,303 common shares, or 10.1% of the class. BlackRock reported sole voting power over 38,300,844 shares and sole dispositive power over 38,673,303 shares, with no shared voting or dispositive power. The reported holdings reflect certain BlackRock business units and affiliates. BlackRock also stated that various persons may direct dividends or sale proceeds, but no one person’s interest exceeds 5% of the class.
LifeStance Health Group, Inc. CEO David Bourdon reported gifts of 150,000 shares of common stock to each of The KMB 2026 Grantor Retained Annuity Trust and The DPB 2026 Grantor Retained Annuity Trust on September 22, 2026. The entries also report corresponding indirect holdings of 150,000 shares in each trust. An immediate family member is the sole trustee and annuitant of the KMB trust; Bourdon is the sole trustee and annuitant of the DPB trust. No Rule 10b5-1 plan is reported.
LifeStance Health Group, Inc. (LFST) reported that entities associated with TPG GP A, LLC, James G. Coulter, and Jon Winkelried indirectly sold 18,409,705 shares of common stock on September 11, 2026 at $12.29 per share in an open-market or private transaction. After this sale, TPG VIII Lynnwood Holdings Aggregation, L.P., the TPG-affiliated entity referenced in the footnotes, directly held 79,691,702 shares of LifeStance common stock. The reporting persons state that they may be deemed to beneficially own these securities only to the extent of their respective pecuniary interests and expressly disclaim beneficial ownership beyond that. No Rule 10b5-1 trading plan is reported for this transaction.
LifeStance Health Group, Inc. (LFST) announced that it entered into an Underwriting Agreement with Barclays Capital Inc. and certain selling stockholders for an underwritten secondary offering of 22,250,000 shares of its common stock under an existing Form S-3 registration statement.
All offered shares were sold by the selling stockholders, and the company received no proceeds from the offering. Under the same agreement, LifeStance agreed to purchase 2,000,000 of those shares from the underwriter at the same price the underwriter paid the selling stockholders. The underwriter did not receive compensation for the shares repurchased by the company. The offering closed on September 11, 2026.
LifeStance Health Group, Inc. (LFST) has filed a prospectus supplement for a secondary offering of 22,250,000 shares of common stock by existing selling stockholders. LifeStance is not issuing new shares and will not receive any proceeds from the stockholders’ sales.
Contingent on the closing of this offering, LifeStance intends to repurchase 2,000,000 of the offered shares from the underwriter for approximately $24.58 million, funded with cash on hand under its existing share repurchase program. The shares purchased in the repurchase will be retired and will no longer be outstanding. LFST common stock trades on Nasdaq under the symbol LFST.
LifeStance Health Group, Inc. (LFST) has filed a preliminary prospectus supplement for a secondary offering of 22,250,000 shares of common stock, all to be sold by existing selling stockholders. LifeStance is not issuing new shares and will not receive proceeds from these sales; the selling stockholders will receive the offering proceeds.
Conditioned on the completion of the offering, LifeStance intends to repurchase 2,000,000 shares from the underwriter using cash on hand under its existing share repurchase program and then retire those shares, which will no longer be outstanding. This repurchase is contingent on the offering’s closing, while the offering itself is not conditioned on the repurchase. Shares outstanding were 382,154,147 as of September 1, 2026, and LFST last traded at $12.80 on September 8, 2026.
LifeStance Health Group, Inc. (LFST) reported that Chief Executive Officer and director David Bourdon transferred 150,000 shares of common stock on September 2, 2026 in an "other acquisition or disposition" transaction. According to the disclosure, the shares were transferred to a family member for no value for estate planning purposes, and Bourdon now holds 1,248,247 shares directly.
LifeStance Health Group, Inc. (LFST) reported that Chief Technology Officer Vukasin Paunovich sold 42,067 shares of common stock on September 2, 2026 in a sale characterized as an open market or private transaction at a weighted average price of $12.87 per share, with individual trades ranging from $12.86 to $12.905. After this transaction, he directly owned 205,379 shares of LifeStance common stock.
LifeStance Health Group, Inc. (LFST) is the issuer of common stock for which Vaughn (Vukasin) Paunovich has filed a Rule 144 notice to sell shares held at Fidelity Brokerage Services LLC. The notice covers 42,067 shares of common stock that vested as restricted stock on June 11, 2026, received from the issuer as compensation. The filing also reports that Paunovich sold 44,394 shares of LFST common stock in the prior three months on August 10, 2026.